Fig 1.
Patient disposition and clinical outcomes.
A total of 156 patients were included for HBsAg-positive cancer patients in our institution who underwent chemotherapy and did not receive anti-viral prophylaxis between the periods of July 2007 to January 2013.
Table 1.
Characteristics of the 156 HBsAg-positive cancer patients who received chemotherapy without antiviral prophylaxis.
Table 2.
Severe acute exacerbation of HBV infection in HBsAg-positive cancer patients who received chemotherapy without antiviral prophylaxis.
Table 3.
Univariate analysis for the clinical factors related to severe acute exacerbation of HBV infection in HBsAg-positive cancer patients who received chemotherapy without anti-viral prophylaxis.
Table 4.
Clinical features of the ten patients who developed severe acute exacerbation of chronic HBV infection.